G
Galapagos NV (GLPG)
NMS – Real Time Price. Currency in USD
27.73
+27.73 (0.00%)
At close: May 7, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
27.73
+27.73 (0.00%)
At close: May 7, 2026, 4:00 PM EDT
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| Name | Position |
|---|---|
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Head of Investor Relations |
| Dr. Jeevan Shetty | Head of Clinical Development Oncology |
| Marieke Vermeersch | Head of Corporate Communication |
| Mr. Aaron L. Cox | Chief Financial Officer |
| Mr. Fred W. Blakeslee II | Executive VP & General Counsel |
| Mr. Henry Gosebruch | CEO & Executive Director |
| Ms. Annelies Missotten | Executive Officer |
| Ms. Ellen Van Der Aar | Head of Development |
| Ms. Tania Philipp | Chief Human Resources Officer |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 6-K | f6k_050626.htm |
| 2026-04-29 | 6-K | tm2612973d1_6k.htm |
| 2026-03-31 | 6-K | d927249d6k.htm |
| 2026-03-30 | 6-K | d54917d6k.htm |
| 2026-03-26 | 20-F | glpg-20251231x20f.htm |
| 2026-03-24 | 6-K | f6k_032326.htm |
| 2026-03-17 | 6-K | f6k_031726.htm |
| 2026-03-10 | 6-K | f6k_031026.htm |
| 2026-03-06 | 6-K | f6k_030626.htm |
| 2026-03-05 | 6-K | f6k_030526.htm |